Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan

Abstract

Despite the first approval of biosimilars’ in 2010, biosimilar products usage has remained low in Taiwan. This cross-sectional survey study assessed healthcare professionals’ (HCPs)—hospital pharmacists, oncologists, and rheumatologists—knowledge, and attitudes toward biosimilars. More precisely, their knowledge and attitude towards biosimilars’ current usage and regulations in Taiwan were analyzed. The mean ± standard deviation knowledge score was 2.56 ± 0.86 out of 4 (n = 395), and a difference in knowledge score was determined according to the hospital types (p = 0.004). Rheumatologists possessed significantly higher confidence in their knowledge of biosimilars than other HCPs (p = 0.001). Pharmacists showed the highest acceptance—and rheumatologists the least—for switching patients from reference drugs to biosimilars (p = 0.02). Hospital type was associated with the respondent’s confidence in their knowledge (p = 0.04) and the preference for distinguishable naming of biosimilars (p = 0.007). Their knowledge scores were associated with their confidence in the efficacy and safety of biosimilars (p = 0.02). The study found that the current level of biosimilar knowledge of HCPs in Taiwan is low. The higher the knowledge score, the greater the confidence in biosimilars and the familiarity with relevant regulations.

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China

“…Studies showed that physicians with less clinical experience tended to choose more expensive imported medicines to satisfy patients or avoid medical responsibilities caused by poor treatment effects in Chinese healthcare settings ( Zhu, 2012 ; Hu et al, 2022 ). Foreign studies also reported that physicians with more clinical experience or higher academic ranks were more confident in choosing biosimilars for patients with complex symptoms ( Cook et al, 2019 ; Poon et al, 2021 ).…”

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

“…It is likely that pharmacists with more knowledge about biosimilars hold more positive perceptions and are, therefore, more confident in providing education. 37 Similarly, more experiences with biosimilars, such as those who regularly educate patients, are likely to translate to more confidence. These findings should be considered when developing future biosimilar transitioning programs, as a lack of knowledge and confidence can unintentionally promote misinformation and disparagement about biosimilars and increase patient hesitancy.…”

Nurses’ Knowledge and Attitudes towards Biosimilar Medicines as Part of Evidence-Based Nursing Practice—International Pilot Study within the Project Biosimilars Nurses Guide Version 2.0

“…In a review by Leonard et al, US and European health care providers were shown to continue to be cautious about biosimilar medicines, citing limited knowledge of biosimilars, low comfort on the part of doctors in prescribing them, and concerns about safety and efficacy [ 12 ]. In order to achieve the cost savings potential of biosimilars, education of clinicians will be necessary to fill the gaps in their knowledge [ 13 ]. Gökdemir et al showed that the general knowledge of doctors about biosimilar medicines was low, and that they had doubts about the effectiveness and safety of biosimilar medicines, which may be related to the lack of knowledge.…”